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Step-Up Therapy in Black Children
and Adults with Poorly Controlled Asthma
M.E. Wechsler, S.J. Szefler, V.E. Ortega, J.A. Pongracic, V. Chinchilli, J.J. Lima,
J.A. Krishnan, S.J. Kunselman, D. Mauger, E.R. Bleecker, L.B. Bacharier,
A. Beigelman, M. Benson, K.V. Blake, M.D. Cabana, J.-C. Cardet, M. Castro,
J.F. Chmiel, R. Covar, L. Denlinger, E. DiMango, A.M. Fitzpatrick, D. Gentile,
N. Grossman, F. Holguin, D.J. Jackson, H. Kumar, M. Kraft, C.F. LaForce, J. Lang,
S.C. Lazarus, R.F. Lemanske, Jr., D. Long, N. Lugogo, F. Martinez, D.A. Meyers,
W.C. Moore, J. Moy, E. Naureckas, J.T. Olin, S.P. Peters, W. Phipatanakul, L. Que,
H. Raissy, R.G. Robison, K. Ross, W. Sheehan, L.J. Smith, J. Solway, C.A. Sorkness,
L. Sullivan‑Vedder, S. Wenzel, S. White, and E. Israel, for the NHLBI AsthmaNet*

A BS T R AC T
BACKGROUND

Morbidity from asthma is disproportionately higher among black patients than among
white patients, and black patients constitute the minority of participants in trials informing treatment. Data indicate that patients with inadequately controlled asthma benefit
more from addition of a long-acting beta-agonist (LABA) than from increased glucocorticoids; however, these data may not be informative for treatment in black patients.
METHODS

We conducted two prospective, randomized, double-blind trials: one involving children
and the other involving adolescents and adults. In both trials, the patients had at least
one grandparent who identified as black and had asthma that was inadequately controlled with low-dose inhaled glucocorticoids. We compared combinations of therapy,
which included the addition of a LABA (salmeterol) to an inhaled glucocorticoid (flu
ticasone propionate), a step-up to double to quintuple the dose of fluticasone, or both.
The treatments were compared with the use of a composite measure that evaluated
asthma exacerbations, asthma-control days, and lung function; data were stratified
according to genotypic African ancestry.

The authors’ full names, academic degrees, and affiliations are listed in the
Appendix. Address reprint requests to
Dr. Wechsler at National Jewish Health,
1400 Jackson St., Denver, CO 80206, or at
wechslerm@njhealth.org, or to Dr. Israel
at Brigham and Women’s Hospital, 75
Francis St., Boston, MA 02115, or at
eisrael@partners.org.
*A complete list of the investigators in
the NHLBI AsthmaNet is provided in the
Supplementary Appendix, available at
NEJM.org.
N Engl J Med 2019;381:1227-39.
DOI: 10.1056/NEJMoa1905560
Copyright © 2019 Massachusetts Medical Society.

RESULTS

When quintupling the dose of fluticasone (to 250 μg twice a day) was compared with
adding salmeterol (50 μg twice a day) and doubling the fluticasone (to 100 μg twice a
day), a superior response occurred in 46% of the children with quintupling the fluticasone and in 46% of the children with doubling the fluticasone and adding salmeterol
(P = 0.99). In contrast, more adolescents and adults had a superior response to the addition of salmeterol than to an increase in the fluticasone (salmeterol–low-dose fluticasone vs. medium-dose fluticasone, 49% vs. 28% [P = 0.003]; salmeterol–medium-dose
fluticasone vs. high-dose fluticasone, 49% vs. 31% [P = 0.02]). Neither the degree of
African ancestry nor baseline biomarkers predicted a superior response to specific treatments. The increased dose of inhaled glucocorticoids was associated with a decrease
in the ratio of urinary cortisol to creatinine in children younger than 8 years of age.
CONCLUSIONS

In contrast to black adolescents and adults, almost half the black children with
poorly controlled asthma had a superior response to an increase in the dose of an
inhaled glucocorticoid and almost half had a superior response to the addition of a
LABA. (Funded by the National Heart, Lung, and Blood Institute; BARD ClinicalTrials
.gov number, NCT01967173.)
n engl j med 381;13
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nhaled glucocorticoids are effective first-line therapies for asthma control, but
when asthma remains poorly controlled, the
recommended treatment is the addition of a longacting β2-adrenergic receptor agonist (LABA).1-9
However, this recommendation is based on studies that included few patients who identified as
black and does not account for differences in
genetic ancestry.
Epidemiologic studies involving patients with
asthma in the United States show a disproportionately greater burden of asthma (exacerbations,
asthma-related urgent-care visits, hospitalizations,
and deaths) in persons identified as “black” than
in those identified as “white.”10-17 Although these
disparities in asthma morbidity may be due to social, environmental, or cultural factors, such trends
persist even after adjustment for contextual factors for which race or ethnic group may serve as
surrogates.13-15,18 Studies show that black patients
often have differential responses to medications
for asthma, and they have more glucocorticoid
resistance, less cellular sensitivity to glucocorticoids, and more eosinophilic inflammation during
inhaled glucocorticoid treatment than do white
patients.19,20 Furthermore, the response to pharmacotherapy for asthma can be affected by genetic
variants that are distributed differentially among
persons of diverse self-described races and ancestral backgrounds; these variants may contribute to
differences between black patients and white patients with respect to the response to β2-agonists
and inhaled glucocorticoids.21-27
Contrary to the findings in white patients,4-8
a subanalysis involving black patients in one study
indicated that adding a LABA was not superior to
increasing the dose of an inhaled glucocorticoid
in persons who identify as black.8 In addition, a
follow-up analysis showed that this finding occurred in black children with eczema.28 Furthermore, a retrospective study involving black adults
suggested that the addition of LABAs may not
confer the same benefit as an increased dose of
inhaled glucocorticoids.29
We conducted two parallel Best African American Response to Asthma Drugs (BARD) trials to
determine the preferred “step-up” strategy in children, adolescents, and adults who had at least one
grandparent who identified as black. We further
examined the extent to which biomarkers, patient
characteristics, and ancestral informative genom-
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ic variation were predictive of a response to inhaled
glucocorticoids or LABAs.

Me thods
Overview of the Trials

We conducted two prospective, randomized, double-blind, four-treatment, four-period, 56-week
crossover trials. One trial involved children (5 to
11 years of age) with at least one grandparent
who identified as black, and the other involved
adolescents and adults who were 12 years of age
or older and who had family backgrounds that
were similar to those of the children. Patients in
both trials had inadequately controlled asthma
while receiving a low-dose inhaled glucocorticoid
(fluticasone propionate at a dose of 50 μg twice
daily in children and 100 μg twice daily in adolescents and adults) (Fig. S1 in the Supplementary Appendix, available with the full text of this
article at NEJM.org).
In the trial involving children, we compared
the efficacy of doubling the dose of an inhaled
glucocorticoid (fluticasone propionate) to a dose
of 100 μg, administered twice daily (the doublefluticasone group); doubling the dose of fluticasone to 100 μg and adding a LABA (salmeterol)
at a dose of 50 μg (the salmeterol–double-fluticasone group); quintupling the dose of fluticasone
to 250 μg (the quintuple-fluticasone group); or
quintupling the dose of fluticasone to 250 μg and
adding salmeterol at a dose of 50 μg (the salmet
erol–quintuple-fluticasone group). Owing to the
lack of a low-dose inhaled glucocorticoid–LABA
combination (i.e., salmeterol–fluticasone propionate, both at a dose of 50 μg), we could not examine the effect of merely adding salmeterol to
the baseline dose of inhaled glucocorticoid.
In the trial involving adolescents and adults,
we compared the efficacy of adding twice-daily
salmeterol at a dose of 50 μg to baseline twicedaily administration of fluticasone propionate
at a dose of 100 μg (the salmeterol–fluticasone
group); increasing the dose of fluticasone by a factor of 2.5 to 250 μg (the 2.5-fluticasone group);
quintupling the dose of fluticasone to 500 μg (the
quintuple-fluticasone group); or increasing the
dose of fluticasone by a factor of 2.5 to 250 μg and
adding salmeterol at a dose of 50 μg (the salmet
erol–2.5-fluticasone group).
The trials were identical in design and step-up
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dosing strategies. However, the first step-up regimen was different in the two trials because of the
above-described differences in available formulations for children.

they were found to have inadequately controlled
asthma within 2 to 10 weeks after they entered
the run-in period (Section 2 in the Supplementary
Appendix).

Oversight of the Trials

Treatment Periods

The trial was funded by the National Heart, Lung,
and Blood Institute (NHLBI) and approved by the
AsthmaNet steering committee, an NHLBI-appointed protocol review committee, and a data and
safety monitoring board. The authors vouch for
the accuracy and completeness of the data, for the
accuracy of the analyses, and for the fidelity of
the trial to the protocol (available at NEJM.org).
GlaxoSmithKline donated the medications for the
trials but did not have any other role in the design
of the trials, in the collection or interpretation of
the data, or in the preparation of the manuscript.

Patients who met the randomization criteria (Section 2 in the Supplementary Appendix) were randomly assigned to step-up treatment sequences in
a four-way crossover design with add-on LABA,
different strengths of increased doses of inhaled
glucocorticoid, or an increased dose of inhaled
glucocorticoid with LABA in dry-powder Diskus
inhalers (Fig. S1 in the Supplementary Appendix). Each treatment period lasted 14 weeks. The
initial 2 weeks of each period were considered to
be a washout period for the previous treatment and
a wash-in period for the new regimen. Data on
asthma-control days during those 2 weeks were
censored from the analyses.

Patients

Patients of both sexes who were 5 years of age
or older and who reported having or (in the case
of children) were reported by a parent or guardian
as having at least one black grandparent were
recruited from nine AsthmaNet partnership sites.
The patients had a baseline forced expiratory volume in 1 second (FEV1) of at least 40% of the
predicted value after bronchodilator use (after four
puffs of albuterol [90 μg per puff]) as well as a
diagnosis of asthma confirmed by beta-agonist
reversibility (an increase in the FEV1 of at least
12%), a methacholine provocation concentration
causing a 20% decrease (PC20) in the FEV1 of 16 mg
per milliliter or less, or an absolute difference in
the percentage of the predicted FEV1 of at least
12 percentage points over two measurements
documented within the previous year (Section 1 in
the Supplementary Appendix).
Run-in Period

Patients who were receiving an inhaled glucocorticoid or an inhaled glucocorticoid–LABA combination were included in the trials, except for those
who had inadequately controlled asthma while
they were receiving a high-dose inhaled glucocorticoid–LABA. The run-in period consisted of an
open-label inhaled glucocorticoid (fluticasone propionate at a dose of 50 μg twice daily in children
and fluticasone propionate at a dose of 100 μg
twice daily in patients who were at least 12 years
of age). Patients could undergo randomization if

n engl j med 381;13

Primary Outcomes

The primary aims of these trials were to evaluate
the superiority of different treatments and the effect of the proportion of African ancestry (as informed by ancestry informative markers as detailed below) on the composite clinical outcome.
The primary clinical outcome of each trial was a
hierarchical composite measure that sequentially
evaluated asthma exacerbations (Section 3 in the
Supplementary Appendix), asthma-control days,
and the percentage of the predicted FEV1 at the
end of the 14-week treatment regimens to determine a differential response.8 A treatment was
deemed to be superior to another if there was a
between-treatment differential response of at least
one exacerbation, defined as worsening asthma
events leading to treatment with systemic glucocorticoids or unscheduled health care utilization.
If no exacerbation difference was identified, a differential of 31 annualized asthma-control days was
evaluated, and if no differential in asthma-control days was identified, then an absolute difference of 5 percentage points in the percentage of
the predicted FEV1 was evaluated. (The primary
and prespecified comparisons are described in
Section 7 in the Supplementary Appendix.)
Whole-blood DNA was genotyped with the use
of Illumina Multi-Ethnic Global Array BeadChips
and 117,053 informative single-nucleotide polymorphisms (linkage disequilibrium, r2≥0.1) select-
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ed for estimation of genetic ancestry. Genotype
data were analyzed with 225 HapMap founders
representing founders with ancestry from northern and western Europe (described in the Centre
d’Etude du Polymorphisme Humain HapMap samples) and central west Africa (Yoruba) (http://ftp
.ncbi.nlm.nih.gov/hapmap/) and 43 Native Americans to estimate the percentage of African, European, and Native American ancestry in each patient.30-32 Ancestry-based genetic analyses evaluated
the association of the percentage of African ancestry with the primary composite outcome (Section 7
and Fig. S6 in the Supplementary Appendix).
Secondary Outcomes

Secondary outcomes included asthma-control days
(according to the use of albuterol rescue, use of
glucocorticoids, symptoms, unscheduled office
visits, and peak flows that were <90% of the reference value determined during the run-in period
for each patient) (Section 3 in the Supplementary
Appendix); the FEV1, before or after bronchodilator use; and measures of asthma control. Asthma
control was also assessed with the use of the
Childhood Asthma Control Test (in which scores
range from 0 [uncontrolled] to 27 [well controlled],
with a minimally important difference of 2) and
the Asthma Control Test (in which scores range
from 5 [uncontrolled] to 25 [well controlled], with
a minimally important difference of 3); higher
values represent better asthma control in both
instruments. Quality of life was assessed with
the use of the Asthma Quality of Life Questionnaire (AQLQ) (in which scores range from 1 to
7 and higher scores represent less impairment,
with a minimally important difference of 0.5).
Exploratory Outcomes

The number and type of asthma exacerbations
(i.e., visits to the emergency department and hospitalizations) were evaluated. Patient characteristics, including atopy, pulmonary function (e.g., the
degree of bronchodilator reversibility and the degree of methacholine responsiveness), and selective
biomarkers, (e.g., sputum eosinophils) were examined to evaluate the differential response to trial
treatments.
Systemic Effects

Overnight urine specimens were obtained for measurements of the ratio of cortisol to creatinine at
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baseline and after treatment intervals. Recent data
from the AsthmaNet Step Up Yellow Zone Inhaled
Corticosteroids to Prevent Exacerbations trial33
showed a reduced linear growth rate associated
with the use of high-dose glucocorticoids among
children younger than 8 years of age, so we analyzed data stratified according to ages younger
than 8 years and 8 years or older.
Statistical Analysis

In the primary analysis, the target sample size of
284 children and 291 adolescents and adults had
90% power with a two-sided alpha of 0.05 to identify an absolute difference of 20 percentage points
in the percentage of patients with a superior response to one therapy over another for the composite asthma outcome, assuming a withdrawal
rate of 20% among children and 35% among
adults before complete trial data acquisition. This
analysis modeled the probability of patients having a superior response to one specific treatment
over another, defined according to the composite
outcome. The composite outcome and its components were fit with the use of nonlinear mixedeffect models for each pair of treatment comparisons (Section 7 in the Supplementary Appendix).34,35
In the trial involving children (5 to 11 years
of age), the primary prespecified comparison was
between fluticasone propionate at a dose of 250 μg
twice daily (quintuple fluticasone) and twice-daily
fluticasone propionate at a dose of 100 μg plus
salmeterol at a dose of 50 μg (salmeterol–double
fluticasone). In the trial involving adolescents and
adults, we were able to directly examine step-up
regimens with a LABA as compared with increased doses of a glucocorticoid (at two doses),
and we prespecified two primary comparisons:
fluticasone propionate at a dose of 250 μg twice
daily (2.5-fluticasone) versus twice-daily fluticasone at a dose of 100 μg plus salmeterol at a dose
of 50 μg (salmeterol–fluticasone), and twice-daily
fluticasone at a dose of 500 μg (quintuple fluticasone) versus twice-daily fluticasone at a dose of
250 μg plus salmeterol at a dose of 50 μg (salmeterol–2.5-fluticasone), without adjustment for
multiple testing. (Section 7 in the Supplementary
Appendix lists prespecified secondary comparisons of the other dose combinations.) The results of the trial involving children and those of
the trial involving adults and adolescents were
also compared.
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(Fig. 1E). (Differential responses to increasing the
dose of inhaled glucocorticoid as compared with
Baseline Characteristics of the Patients
adding a LABA in the elements of the composite
Between January 2014 and March 2016, a total of of FEV1, asthma-control days, or exacerbations
280 children (of 482 enrolled) and 294 adoles- are shown in Figures S4.1 through S4.3 in the
cents and adults (of 536 enrolled) underwent Supplementary Appendix.)
randomization at nine centers (Figs. S2 and S3
and Table S1 in the Supplementary Appendix). Outcomes in Adolescents and Adults
The majority of children were male, and the In all the comparisons in the trial involving adomajority of adolescents and adults were female lescents and adults, 20 to 25% of the patients did
(Table 1). As compared with the adolescents and not have a differential outcome between treatadults, more children had a blood eosinophil count ments (Fig. 2). More adolescents and adults had
of at least 300 cells per cubic millimeter, and a superior response with the addition of a LABA
children had a higher percentage of the predicted than with either of the two step-up dose increasFEV1, more courses of systemic glucocorticoids, es in inhaled glucocorticoids (49% in the salmeand more unscheduled office visits and hospital- terol–fluticasone group vs. 28% in the 2.5-flutiizations because of asthma in the previous year. casone group) (P = 0.003) (Fig. 2A), and 49% in
(Complete baseline characteristics of the patients the salmeterol–2.5-fluticasone group versus 31%
and of those who completed the trials as compared in the quintuple-fluticasone group (P = 0.02)
with those who discontinued the trials are provid- (Fig. 2C). Differences in superior response rates
ed in Table S1 in the Supplementary Appendix.)
were driven by differences in asthma-control days
and FEV1 (Figs. S5.2A and S5.2B and S5.3A and
Outcomes in Children
S5.3B in the Supplementary Appendix). ExacerThe majority of children had a differential outcome bations were infrequent and contributed only
between treatments. The maximum percentage of minimally to the composite outcome (Fig. S5.1.A
patients who did not have a superior response in and S5.1.B in the Supplementary Appendix). Inany paired intervention comparison was 12% creasing the dose of glucocorticoid by either a
(Fig. 1). There was no significant difference in factor of 2.5 (fluticasone propionate at a dose of
the probability of a superior response when the 250 μg) or a factor of 5 (fluticasone propionate
dose of inhaled glucocorticoid was increased two at a dose of 500 μg) (Fig. 2D) or from 100 μg of
steps to a quintupled dose of fluticasone propio- fluticasone propionate to 250 μg of fluticasone
nate (250 μg) (46% superior) as compared with propionate (accompanied by a LABA) (Fig. 2E) did
a two step-up strategy of adding a LABA (salmet not result in a significantly higher percentage of
erol) at a dose of 50 μg and increasing the dose patients with a superior response.
of fluticasone to 100 μg (46% superior) (P = 0.99)
Comparison of the Two Trials
(Fig. 1B).
In children, 53% of patients (95% confidence In adolescents and adults, the addition of a LABA
interval [CI], 45 to 61) in the salmeterol–double- was more likely to produce superior responses
fluticasone group had a superior response, as than increasing the dose of an inhaled glucocorcompared with 41% (95% CI, 33 to 49) in the ticoid. In contrast, children had a response to
double-fluticasone group (Fig. 1A), whereas 43% stepped increases in the dose of inhaled glucocor(95% CI, 35 to 52) in the salmeterol–quintuple- ticoid (Fig. 3A, and Figs. S4 and S5 in the Supplefluticasone group had a superior response, as mentary Appendix).
compared with 47% (95% CI, 39 to 56) in the the
quintuple-fluticasone group (Fig. 1C). A total of Secondary Outcomes
51% of patients (95% CI, 42 to 59) had a superior The results of prespecified secondary outcomes
response to a higher dose of inhaled glucocorti- and analyses are provided in Figures S4 and S5
coid (in the quintuple-fluticasone group) as com- and Table S8 in the Supplementary Appendix.
pared with 37% of patients (95% CI, 29 to 45) who Consistent with the trend seen in the evaluation
had a superior response to a lower dose of inhaled of the composite outcome, more children had reglucocorticoid (in the double-fluticasone group) duced asthma exacerbations with a higher dose of
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Table 1. Characteristics of the Patients at Baseline.*

Characteristic

Children
(5–11 Yr)
(N = 280)

Adolescents and Adults
(≥12 Yr)
(N = 294)

Demographic features
8.5±1.8

37.3±16.1

Male sex — no. (%)

Age — yr

170 (60.7)

95 (32.3)

Median percentage of African ancestry (IQR)†

81.0 (73.4–85.6)

Hispanic ethnic group — no. (%)‡

82.1 (75.3–87.6)

24 (8.6)

9 (3.1)

208 (74.3)

132 (44.9)

Asthma history in previous 12 mo — no. (%)
One or more asthma episodes resulting in emergency care or unscheduled
office visit
One or more overnight hospitalizations
One or more courses of systemic glucocorticoids

43 (15.4)

14 (4.8)

172 (61.4)

99 (33.7)

107 (38.2)

50 (17.0)

Medications used in previous 12 mo
Leukotriene-receptor antagonist or 5-lipoxygenase inhibitors — no. (%)
Oral glucocorticoids — no./total no. (%)

170/277 (61.4)

92/293 (31.4)

Inhaled or nebulized glucocorticoid monotherapy — no./total no. (%)

246/279 (88.2)

193/294 (65.6)

Inhaled glucocorticoid–LABA combination therapy — no./total no. (%)

64/279 (22.9)

139 /294 (47.3)

224/273 (82.1)

244/287 (85.0)

Clinical and spirometric features
Patients with ≥1 of 13 positive tests for allergens by ImmunoCAP assay —
no./total no. (%)
Sputum eosinophil level ≥2% — no./total no. (%)§
Median blood eosinophil absolute count —

cells/mm3

NA
(IQR)¶

Median serum total IgE — IU/ml (IQR)‖
FEV1 — % of predicted value**
Bronchodilator response (4 puffs) — % relative change††

24/220 (10.9)

340 (200–510)

200 (100–300)

286.5 (92.0–693.5)

174.0 (73.0–468.0)

95.5±16.7

83.4±17.4

13.79±14.48

12.47±12.43

PC20 for methacholine — mg/ml‡‡
Geometric mean

1.32

1.71

Coefficient of variation

1.61

1.60

Median score on Childhood Asthma Control Test or Asthma Control Test
(IQR)§§

22 (19–24)

19 (16–22)

Asthma-control days during 2 wk before randomization (%)¶¶

31.2±29.9

24.5±28.2

*	Plus–minus values are means ±SD. FEV1 denotes forced expiratory volume in 1 second, LABA long-acting beta-agonist, and NA not applicable.
†	Data were missing for 15 children and 10 adolescents and adults.
‡	Race and ethnic group were reported by the patients or their parents or guardians.
§	Children younger than 12 years of age did not undergo sputum induction.
¶	Data were missing for 5 children and 5 adolescents and adults.
‖	Data were missing for 4 children and 4 adolescents and adults.
**	Data were missing for 5 children and 3 adolescents and adults.
††	Data were missing for 7 children.
‡‡	PC20 denotes the provocative concentration of inhaled methacholine that results in a 20% reduction in the FEV1. Data were missing for
67 children and 44 adolescents and adults.
§§	The score on the Childhood Asthma Control Test ranges from 0 to 27, with higher values representing better asthma control. The score on
the Asthma Control Test ranges from 5 to 25, with higher values representing better asthma control. Data were missing for 1 patient in
each group.
¶¶	Patients who provided asthma-control information on fewer than 7 of the 14 days were excluded from this summary, and data were missing for 3 children and 5 adolescents and adults.
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Figure 1. Percentage of Black Children (5 to 11 Years of Age) with Asthma Who Had a Superior Response to Specific Treatments,
According to the Composite Outcome, at 14 Weeks.
Shown are the five prespecified comparisons of the percentages of patients with a superior response among those receiving twice-daily
treatment with a low-dose inhaled glucocorticoid (fluticasone propionate) at a dose of 50 μg (FP100, the double-fluticasone group);
a dose of fluticasone doubled to 100 μg with the addition of a LABA (salmeterol) at a dose of 50 μg (FP100/SM50, the salmeterol–double-fluticasone group); a dose of fluticasone quintupled to 250 μg (FP250, the quintuple-fluticasone group); or a dose of fluticasone
quintupled to 250 μg with the addition of salmeterol at a dose of 50 μg (FP250/SM50, the salmeterol–quintuple-fluticasone group) with
respect to the hierarchical composite outcome that incorporated asthma exacerbations, asthma-control days, and change in the forced
expiratory volume in 1 second (FEV1). The numbers in each bar represent the percentage of patients who had a superior response to
that specific treatment, as compared with the alternative treatment. Gray bars indicate the percentage of patients in whom one treatment was not superior to the other. The P value reflects a test of the coprimary null hypothesis that the probability of a superior response
to each treatment would not differ. T bars indicate 95% confidence intervals.

inhaled glucocorticoid (7%; 95% CI, 2 to 13)
than with a lower-dose of inhaled glucocorticoid
(2%; 95% CI, 0 to 5). Higher-dose inhaled glucocorticoids also produced greater changes in the
percentage of the predicted FEV1 before or after
bronchodilator use (2.3%; 95% CI, 0.7 to 4.0) than
a lower-dose inhaled glucocorticoid (1.6%; 95% CI,
0.1 to 3.0).
Adolescents and adults had more asthma-control days with the addition of a LABA than with
an increase in the dose of inhaled glucocorticoid

n engl j med 381;13

(a 14-day-per-year difference [95% CI, 1 to 26] in
the salmeterol–fluticasone group vs. the 2.5-flu
ticasone group and a 14-day-per-year difference
[95% CI, 3 to 25] in the salmeterol–2.5-fluticasone group vs. the quintuple-fluticasone group)
(Table S8 in the Supplementary Appendix). There
was also an absolute difference in the percentage
of the predicted FEV1 before bronchodilator use
(the salmeterol–fluticasone group vs. the 2.5-flu
ticasone group, 1.2 percentage points [95% CI,
0.2 to 2.3]; and the salmeterol–2.5-fluticasone
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Figure 2. Percentage of Black Adolescents and Adults with Asthma Who Had a Superior Response to Specific Treatments, According to
the Composite Outcome, at 14 Weeks.
Shown are all the comparisons of the percentages of patients with a superior response among those receiving twice-daily treatment
with fluticasone propionate at a dose of 100 μg plus salmeterol at a dose of 50 μg (FP100/SM50, the salmeterol–fluticasone group);
a dose of fluticasone increased by a factor of 2.5 to 250 μg (FP250, the 2.5-fluticasone group); a dose of fluticasone quintupled to
500 μg (FP500, the quintuple-fluticasone group); or a dose of fluticasone increased by a factor of 2.5 to 250 μg with the addition of salmeterol at a dose of 50 μg (FP250/SM50, the salmeterol–2.5-fluticasone group) with respect to the hierarchical composite outcome
that incorporated asthma exacerbations, asthma-control days, and the absolute change in the percentage of the predicted FEV1. The
numbers in each bar represent the percentage of patients who had a superior response to that specific treatment, as compared with the
alternative treatment. Gray bars indicate the percentage of patients in whom one treatment was not superior to the other. The P values
reflect a test of the coprimary null hypotheses that the probability of a superior response to each treatment would not differ. T bars indicate 95% confidence intervals.

group vs. the quintuple-fluticasone group, 0.9 percentage points [95% CI, −0.1 to 1.9]) (Table S8 in
the Supplementary Appendix). However, the addition of a LABA did not differentially affect asthma
exacerbations, the FEV1 after bronchodilator use,
the results of the Asthma Control Test, or the
results of the AQLQ.

of 81.0% in children and 82.1% in adolescents
and adults (Table 1, and Fig. S6 in the Supplementary Appendix); this distribution was comparable to that in black populations in previous
studies.36 There were no significant interactions
between the percentage of African ancestry and
the primary composite outcome or any of the individual outcomes (Tables S2 and S3 in the SupGenetic African Ancestry and Therapeutic
plementary Appendix). We were unable to identify
Outcomes
a cutoff for the percentage of African ancestry
Among patients in both age groups, there was a that was predictive of therapeutic response (Tabroad distribution in the percentage of African bles S4 through S7 in the Supplementary Appenancestry, ranging from 2 to 100%, with a mean dix), and we did not find significant, consistent,
1234
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Figure 3. Comparison of the Primary Composite Outcome in the Trial involving Adolescents and Adults and the Trial involving Children.
Shown are the prespecified comparisons of the percentages of patients with a superior response. Each panel shows a comparison of a
similar step-up in therapy for children and for adolescents and adults. Shown are responses at 14 weeks in adolescents and adults and
in children who at baseline had poorly controlled asthma while receiving twice-daily treatment with a low-dose inhaled glucocorticoid
(fluticasone propionate) (50 μg in children and 100 μg in adolescents and adults). In children, the step-up trial treatments included
doubling the dose of fluticasone to 100 μg (FP100, the double-fluticasone group); doubling the dose of fluticasone to 100 μg and adding
salmeterol at a dose of 50 μg (FP100/SM50, the salmeterol–double-fluticasone group); quintupling the dose of fluticasone to 250 μg
(FP250, the quintuple-fluticasone group); or quintupling the dose of fluticasone to 250 μg and adding salmeterol at a dose of 50 μg
(FP250/SM50, the salmeterol–quintuple-fluticasone group). In adolescents and adults, the step-up interventions included adding salmeterol to the baseline dose of fluticasone (FP100/SM50, the fluticasone–salmeterol group), increasing the dose of fluticasone by a factor of 2.5 (FP250, the 2.5-fluticasone group), increasing the dose of fluticasone by a factor of 2.5 and adding salmeterol (FP250/SM50,
the salmeterol–2.5-fluticasone group), or quintupling the dose of fluticasone (FP 500). A superior response was determined with respect to the hierarchical composite outcome that incorporated asthma exacerbations, asthma-control days, and the change in the FEV1.
The numbers in each bar represent the percentage of patients who had a superior response to that specific treatment as compared with
the alternative treatment. Gray bars indicate the percentage of patients in whom one treatment was not superior to the other. The two
groups of patients (patients from the trial involving children and those from the trial involving adolescents and adults) were compared
to identify interactions between the two groups and the composite superiority outcome. T bars indicate 95% confidence intervals.

meaningful associations between African ancestry and the treatment response when the extremes
of ancestry were compared (Figs. S7.1 and S7.2 in
the Supplementary Appendix).
For the primary composite outcome in both
trials, none of the prespecified biomarkers or patient characteristics identified a group of patients
who were more likely to have a response to the
addition of one therapy than to another.
n engl j med 381;13

Safety

In the trial involving children, the highest dose of
inhaled glucocorticoid (250 μg twice daily) was
associated with a decrease in the ratio of urinary
cortisol to creatinine in those who were younger
than 8 years of age (Table S9 in the Supplementary
Appendix), whereas no such effects were seen in
adolescents and adults. There were no other significant differences among the treatment groups
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in either trial with respect to respiratory tract in- terioration of asthma and thus is not comparable
fections or pneumonia.
to our trials examining the effects of long-term
treatment.
We found evidence of adrenal axis suppression
Discussion
in young children (<8 years of age) (Table S9 in
Studies involving children and adults with asthma the Supplementary Appendix) at the highest dose
have been conducted primarily in white popula- of inhaled glucocorticoid we tested (fluticasone
tions; these studies have shown that when esca- propionate at a dose of 250 μg). Our trial was not
lating asthma therapy, the addition of a LABA is long enough to assess effects on growth. However,
more likely to produce a superior response than the findings with regard to the adrenal axis at high
an increase in the dose of an inhaled glucocor- doses of inhaled glucocorticoids are of potential
ticoid.5-8 These data have influenced guidelines concern, although it is not clear how our findregarding escalation of therapy when patients ings would extrapolate to other formulations of
present with asthma that is not well controlled; inhaled glucocorticoids.
however, black patients with asthma have not
African ancestry, as determined by patterns of
been included in the clinical trials on which the genetic markers, has been associated with asthmaguidelines were based.10,11,13-16
related phenotypes including low lung function
In the current trials, almost half the children and exacerbations.36-38 However, we did not find
who had at least one grandparent who identified that African ancestry was associated with differas black and who had poorly controlled asthma ential responses in adolescents and adults or with
(46%) had improved asthma outcomes when the differential responses in children (Figs. S7.1 and
dose of inhaled glucocorticoid was increased rath- S7.2 in the Supplementary Appendix). Nevertheer than with the addition of a LABA. Furthermore, less, the absence of a global ancestral effect does
we discovered that in contrast to both black not exclude potential effects of either asthma seadults and white adults and white children, black verity loci or pharmacogenetic loci differentially
children had a response to stepped increases in inherited among persons across varying ancesthe dose of inhaled glucocorticoid. Our results tral backgrounds.21-27 We were also not able to deare all the more striking in that in our parallel tect phenotypic or biomarker characteristics that
trial we confirmed that adolescents and adults were associated with a differential response to a
who had at least one grandparent who identified specific therapy. A larger trial might have the
as black had responses similar to those reported power to determine which phenotypic or specific
in white adults — that is, the addition of a LABA pharmacogenetic variant panels could have the
in adults was more likely to lead to superior re- power to detect such differences.
sponses in a larger group of patients than an
In conclusion, our prospective, randomized
increase in the dose of an inhaled glucocorti- BARD trials comparing several strategies of treatcoid. These findings suggest that data cannot be ment escalation for asthma in children and in adoextrapolated from clinical trials involving mixed lescents and adults who had at least one grandparpopulations to specific subgroups, including those ent who identified as black showed that outcomes
of different ages and races.
differed in children and adults, and the results
We found that larger percentages of children in these children differed from those previously
than had been previously reported in mixed popu- reported in studies involving white children. In
lations had a response to increasing doses of contrast to black adults and white persons of all
glucocorticoids than to the addition of a LABA.8 ages, almost half the children who had at least
Although a recent trial involving predominantly one grandparent who identified as black and who
white children with mild-to-moderate persistent had poorly controlled asthma had a superior reasthma showed that quintupling the dose of in- sponse to an increased dose of an inhaled gluhaled glucocorticoids for 7 days at the early signs cocorticoid over the addition of a LABA. A largof loss of asthma control was not better in pre- er, more simplified trial should be undertaken to
venting exacerbations than maintaining the use determine the best treatment approach for black
of low-dose inhaled glucocorticoids,33 that trial children with poorly controlled asthma despite
involved short-term administration of higher-dose the use of standard doses of an inhaled glucoinhaled glucocorticoids in patients with acute de- corticoid.
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